Major histocompatibility complex class II HLA-DR (HLA-DR)

HLA-DR (Major histocompatibility complex class II HLA-DR) is a heterodimeric antigen-presenting receptor that displays processed peptide antigens on the surface of antigen-presenting cells for recognition by CD4+ T lymphocytes. The molecule consists of alpha and beta chains that form a peptide-binding groove capable of accommodating 12-24 amino acid peptides. HLA-DR associates with the invariant chain during biosynthesis to prevent premature peptide loading and functions as a scaffold for proteolytic processing. Peptide selection is stringently regulated through the actions of HLA-DM, which catalyzes peptide loading and dissociation, and HLA-DO, which fine-tunes the antigenic peptide repertoire by preferentially promoting binding of DM-resistant peptides. The target plays a central role in adaptive immunity by enabling recognition of pathogenic and foreign antigens. HLA-DR is also a key player in autoimmune disease susceptibility: specific HLA-DR allelic variants, particularly HLA-DR4 subtypes, are strongly associated with type 1 diabetes, with single amino acid residue differences determining disease risk versus protection. The extensive allelic diversity of HLA-DR (over 200 known variants) reflects both population-specific variation and functional heterogeneity in peptide-binding properties. As a therapeutic target, HLA-DR represents an opportunity for immune-modulating interventions aimed at enhancing immune responses to pathogens or cancer, or conversely, suppressing autoreactive T cell responses in autoimmune and inflammatory conditions. The complexity of HLA-DR biology—involving multiple regulatory proteins, transient molecular interactions, and extensive genetic polymorphism—presents both opportunities and challenges for drug development.

Other names

Human Leukocyte Antigen DRMHC class II antigen DRHLA-DRA/HLA-DRB (component chains)HLA-DR1, HLA-DR2, HLA-DR3, HLA-DR4, HLA-DR5 (allelic variants)MHC II molecules (broader classification)

Modulating HLA-DM or HLA-DO activity to alter which peptides are presented to T cells. Altering the efficiency of peptide loading to enhance desired immune responses or suppress autoreactive responses. Targeting the structural interactions between HLA-DR, invariant chain, and peptide-loading cofactors to modulate antigen presentation.